Akorn reports hike in quarterly revenue
BUFFALO GROVE - Akorn Inc., a specialty pharmaceutical company, Tuesday reported total revenue for the first quarter was $22 million, versus $14.5 million in the first quarter 2008, representing an increase of approximately 52 percent.
The revenue increase was driven by higher Td Vaccine sales, which totaled $10.7 million.
The company's net loss was approximately $10.7 million in the first quarter 2009 as compared to $5.5 million in the first quarter 2008. This reflects a higher gross profit that was offset by nonrecurring expenses.
Akorn Inc. manufactures and markets sterile specialty pharmaceuticals.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.